Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Choose from a selection of modern and traditional designs in single or twin packs to support type 1 diabetes research this Christmas. Shop online and get fast delivery.
Our ambitious new roadmap is aimed at driving significant advancements in type 1 diabetes research, treatment, and care.
Invite your friends, family, colleagues or clients to an exceptional black-tie event in the heart of London.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF has now rebranded to Breakthrough T1D. Our name has changed, our mission has not.
Home > News & Events > Sign up for our newsletter
Subscribe to receive Breakthrough T1D’s e-newsletters and you’ll be the first to know about all of this and more.
We promise to keep your details secure and we won’t share your information with any other organisations. If you decide you’d rather not hear from us then you can unsubscribe at any time.
To sign up, simply complete your details below and click subscribe.
We respect your privacy. We will never share your information with any third party. For full details see our privacy policy.
EASD is Europe’s biggest diabetes conference, bringing together experts from around the world to share research and updates that will improve lives, prevent complications, and bring us closer to better treatments. Here are some of the key takeaways that matter most for our community.
A clinical trial called MELD-ATG, run by the clinical trials network INNODIA, has announced positive results at the European Association for the Study of Diabetes (EASD) conference in Vienna this year. It investigated whether a drug called Anti Thymocyte Globulin (ATG) could help preserve insulin producing cells (beta cells)
A new research paper has presented data that shows people breastfeeding with type 1 diabetes (T1D) need not let higher blood glucose levels stop them from breastfeeding their infants
We’re pleased to announce that we are launching a new initiative to raise awareness of the importance of early detection in type 1 diabetes (T1D), with support from Sanofi.
In a landmark moment, the MHRA has licensed the use of teplizumab in the UK, the first-ever disease-modifying therapy for T1D.
In the study, nearly two thirds of young people diagnosed with type 1 diabetes (T1D) did not have the typical identifiers of the condition.
We've partnered with Barbie to create the world’s first Barbie doll with type 1 diabetes (T1D).
A recent study has shown that a treatment currently used for type 2 diabetes could be used to help prevent kidney damage in young adults with type 1.
